Welcome To ArTara Therapeutics

We are a team of veteran rare disease specialists, passionate about bringing therapies to patients who have limited to no treatment options.
We work with academic and industry partners around the world to find and develop breakthrough therapies that will improve the well-being of patients with rare, neglected, and serious diseases.

PATIENT-CENTERED DRUG DEVELOPMENT

Biotech at its best is a profession of compassion. We are driven by the question, “how will this help the patients we serve?"

EXCELLENCE AND EFFICIENCY

We balance high standards and maximum efficiency to deliver treatments to patients faster.

BUSINESS DEVELOPMENT

We look externally for innovative therapies. We search for assets where our expertise and network can optimize programs that are stalled or need a drug development partner.

BE A FORCE FOR GOOD

We define ourselves through focus, humility and our genuine passion to help patients. We believe that collectively we can do good in the world – for our patients, our employees and beyond.

TARA 002 for the treatment of Lymphatic Malformations (LMs)

Our lead program is TARA 002, an investigational cellular therapy based on OK-432, an immunostimulant currently approved in Japan and Taiwan, that has been standard of care in LMs for over 20 years.  Lymphatic malformations are rare, non-malignant masses that primarily form in the head and neck region of children before the age of two.  Radiographically, lymphatic malformations have been categorized into three subtypes – macrocystic, microcystic, or mixed (a combination of the other two). In the US and Europe, the standard of care is surgical excision, which is associated with high rates of recurrence and complications.1  A US-based, multicenter study in more than 600 patients, led by the University of Iowa, demonstrated that OK-432, was safe and effective in the treatment of macrocystic and mixed LMs.

OK-432 has been granted orphan drug designation by the FDA.

1Perkins, J. et al. Otolaryngology–Head and Neck Surgery. 2010; 142(6):795-803

IV Choline Chloride for the treatment of intestinal failure associated liver disease (IFALD)

ArTara’s second program IV Choline Chloride is being developed for the treatment of Intestinal Failure Associated Liver Disease (IFALD).  IFALD is a devastating disease that impacts a large number of patients who rely on parenteral nutrition (PN) for long-term survival. The etiology of IFALD is considered to be multifactorial with a substantial body of literature implicating choline deficiency as a key cause. IFALD is uniquely characterized by the presence of both steatosis (toxic fat accumulation in liver cells) and cholestasis (damage to the biliary system in the liver). In a phase 2a, randomized, controlled study, treatment with IV choline chloride resulted normalization of plasma-free choline concentrations and clinically meaningful improvements in steatosis and cholestasis in PN-dependent patients. Choline Chloride for Injection has been granted Orphan Drug Designations by the FDA for both the prevention and/or treatment of choline deficiency in patients on long-term parenteral nutrition and treatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term parenteral nutrition.

Latest News

September 23, 2019

Proteon Therapeutics and ArTara Therapeutics Agree to Combine

Transaction to Create NASDAQ-Listed Rare and Specialty Disease Therapeutic Company […]
June 19, 2019

ArTara Therapeutics Announces Initiation of New Immunology Pipeline Program with TARA-002, a Toll-Like Receptor 4 Agonist, Targeting Rare Lymphatic Malformations

February 4, 2019

ArTara Therapeutics Announces Additions to Leadership Team and Board of Directors